Shares of Axon Enterprise rose sharply Thursday after the maker of law-enforcement technology like Tasers and body cameras reported a spike in international sales. Axon stock jumped 7.6% to $415.14 on Thursday.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
Shares of Axon Enterprise rose sharply Thursday after the maker of law-enforcement technology like Tasers and body cameras reported a spike in international sales. Axon stock jumped 7.6% to $415.14 on Thursday.
The Dow Jones Industrial Average was down, while the S&P 500 Index and the Nasdaq Composite were up
IonQ (IONQ) continues to beat quarterly revenue guidance, with momentum remaining strong and the com
Datadog stock is leading software stocks higher after the enterprise tech players reported results ahead of expectations.
The CBOE Volatility Index (VIX) slipped about 1.2% Thursday morning to hover just above the 17 level, extending a steady drift lower from the 31.05 peak set on March 27. The fear gauge is down 28% over the past month and squarely inside the 15 to 20 normal band. With stocks perched near records, the ... VIX Stands Firm as Fear Drains, Stocks Chase Records and Earnings Keep Dip-Buyers Engaged
ORA's Q1 adjusted EPS jumps 91.2% to $1.30, and revenues surge 75.8% to $403.9 million, led by Product and Energy Storage gains.
Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.
AI ransomware and data centers are both driving up demand for Fortinet’s products, analyst Gray Powell said.
MCD beats Q1 2026 estimates as global comps rise 3.8% and systemwide sales top $34B, with loyalty sales exceeding $9B across 70 markets.
Howmet Aerospace cleared estimates driven by commercial, defense engine demand. HWM stock is set to rallied past a buy point.
AppLovin Corp (NASDAQ:APP) reported better-than-expected first quarter results and raised its outlook for the current quarter, driven by continued strength in its AI-powered advertising business. The marketing and advertising technology company posted first-quarter revenue of $1.84 billion,...
Our AppLovin (NASDAQ:APP) call comes at a moment when the stock has recovered ground after a weak first quarter. Shares trade at $468.83 as of writing, and our proprietary model points to meaningful upside from here. The 24/7 Wall St. price target for AppLovin is $576.79, implying 23.03% upside over the next 12 months. Confidence ... AppLovin Price Prediction Raised After Q1 Earnings Beat
AppLovin Delivers Stunning Growth Forecast as AI Ad Business Accelerates
Shares of Peloton Interactive (NASDAQ:PTON) are climbing 11% to $5.76 in premarket trading on Thursday, May 7, after the connected fitness company posted a swing to GAAP profitability and lifted its full-year outlook. The bid follows an 8-K filed at 6:59 a.m. ET and an earnings call that began at 8:30 a.m. ET. The pop ... Peloton Soars 11% on Q3 Profit Turnaround, Raised Guidance, Spotify Partnership
Albemarle reports earnings per share of $2.95 from sales of $1.4 billion. Wall Street was looking for earnings per share of $1.19 from sales of $1.3 billion.
ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Commerce.com (CMRC) delivered earnings and revenue surprises of +21.84% and +4.55%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Celsius Holdings Inc. (NASDAQ:CELH) reported first-quarter results that topped Wall Street expectations, sending shares approximately 6.
Palantir's Explosive AI Growth Forces Analysts to Raise Targets Again
The chip designer reported fourth-quarter profit of $313 million, up from $210 million a year earlier, but stock fell on supply concerns
Snap stock was tumbling after earnings. The cancellation of a deal with AI start-up Perplexity is likely to fuel an activist campaign.
Investing.com -- McDonald’s Corp (NYSE:MCD) reported first-quarter results that exceeded analyst expectations, sending shares around 3.5% higher premarket on Thursday.
Trex (TREX) delivered earnings and revenue surprises of +16.39% and +1.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Enovis (ENOV) delivered earnings and revenue surprises of +8.54% and +3.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Truck broker RXO has offered investors some calm in a sea of Amazon -disruption fears. A year ago, RXO reported Ebitda of $22 million from sales of $1.4 billion. For the second quarter, RXO expects Ebitda of between $27 million and $37 million.
The fast-food chain's global comparable sales rose 3.8% and revenue climbed 9% to $6.52 billion in the first quarter
Arm Holdings (NASDAQ:ARM) reported quarterly earnings and guidance that surpassed Wall Street expectations, while highlighting strong customer demand for its recently launched artificial intelligence-focused data center processor. Despite the upbeat results, U.
AppLovin (NASDAQ:APP), the artificial intelligence-powered mobile advertising company, posted first-quarter revenue and earnings that exceeded Wall Street expectations, supported by continued strong demand for its advertising offerings and AI-enabled tools. The stock gained more than 2% in premarket trading Thursday following the results.
Investing.com -- Celsius Holdings Inc. (NASDAQ:CELH) reported first-quarter results that exceeded analyst expectations, sending shares up around 6.3% premarket on Thursday.
Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S. Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format. The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market. Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a...